181 related articles for article (PubMed ID: 27062282)
1. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ; Chu Y; Hanley PJ; Cairo MS
Br J Haematol; 2016 May; 173(4):597-616. PubMed ID: 27062282
[TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
Hochberg J; El-Mallawany NK; Cairo MS
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
[TBL] [Abstract][Full Text] [Related]
3. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
Herrera AF
Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
[TBL] [Abstract][Full Text] [Related]
4. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
5. The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.
Rezahosseini O; Hanaei S; Hamadani M; Keshavarz-Fathi M; Rezaei N
Int Rev Immunol; 2018 May; 37(3):165-173. PubMed ID: 29257907
[TBL] [Abstract][Full Text] [Related]
6. Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.
Chu Y; Gardenswartz A; Termuhlen AM; Cairo MS
Br J Haematol; 2019 Jun; 185(6):1055-1070. PubMed ID: 30613939
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.
Metzger ML; Mauz-Körholz C
Br J Haematol; 2019 Jun; 185(6):1142-1157. PubMed ID: 30729493
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
9. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
10. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
Jourdan E; Richard B
Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
[TBL] [Abstract][Full Text] [Related]
12. Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
Chu Y; Gardenswartz A; Diorio C; Marks LJ; Lowe E; Teachey DT; Cairo MS
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101442. PubMed ID: 36907635
[TBL] [Abstract][Full Text] [Related]
13. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
14. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
15. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
[TBL] [Abstract][Full Text] [Related]
16. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
17. Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
Galardy PJ; Bedekovics T; Hermiston ML
Br J Haematol; 2016 May; 173(4):625-36. PubMed ID: 27019108
[TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
El-Mallawany NK; Cairo MS
Clin Adv Hematol Oncol; 2015 Feb; 13(2):113-23. PubMed ID: 25774481
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
20. The use of galiximab in non-Hodgkin lymphoma.
Vinjamaram S; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma; 2008 Oct; 8(5):277-82. PubMed ID: 18854281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]